NCI HIGH PRIORITY CLINICAL TRIAL --- Prostatectomy Compared With Watchful Waiting in Treating Patients With Stage I or Stage II Prostate Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
|Phase III||Treatment||Closed||75 and under||NCI||VA-CSP-407|
CALGB-9492, ECOG-VA407, SWOG-9450, PIVOT-1, NCI-T94-0131O, NCT00002606, T94-0131
- Compare the overall mortality rate in patients with clinically localized prostate cancer treated with radical prostatectomy and early intervention for subsequent disease progression vs expectant management with therapy reserved for palliation of symptomatic or metastatic disease.
- Compare the prostate cancer-specific survival of patients treated with these regimens.
- Compare the quality of life of patients treated with these regimens.
- Compare the progression-free survival of patients treated with these regimens.
- Determine the effects of radical prostatectomy on disease recurrence in these patients.
- Adenocarcinoma of the prostate diagnosed within the past year
- Clinically localized disease (T1a-c or T2a-c, NX, M0)
- PSA no greater than 50 ng/mL
- No evidence of metastatic disease on bone scan
- No evidence of nonlocalized disease on other imaging studies
- Not specified
- No prior chemotherapy for prostate cancer
- No prior hormonal therapy for prostate cancer
- No concurrent estrogens or antiandrogens
- No prior radiotherapy for prostate cancer
- No prior surgery for prostate cancer except transurethral resection
- No concurrent participation in another intervention research study
- 75 and under
- Not specified
- At least 10 years
- Not specified
- No severe hepatic impairment
- Creatinine no greater than 3.0 mg/dL
- No severe renal impairment
- No New York Heart Association class III or IV heart disease
- No myocardial infarction within the past 6 months
- No unstable angina
- No other severe cardiac impairment
- No severe pulmonary impairment
- No other significant concurrent medical condition that is acute or debilitating or would increase risk
- No dementia
- No nondermatologic malignancy within the past 5 years
A total of 1,050 patients will be accrued for this study within 7 years.
This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 6 weeks after randomization, patients undergo pelvic lymph node dissection (at the discretion of the urologist) followed within 2 weeks by radical prostatectomy. The choice of surgical procedure (retropubic, perineal, nerve sparing, or nonnerve sparing) is at the discretion of the urologist. Patients with metastases may undergo standard therapy, including prostatectomy, observation, orchiectomy or hormonal therapy, or radiotherapy. Patients with disease progression may undergo standard therapy, including hormonal therapy, radiotherapy, mechanical intervention, or observation.
- Arm II: Patients undergo expectant management with interventions reserved for symptomatic or metastatic disease. Asymptomatic disease progression (e.g., enlarging mass on digital rectal exam or imaging study, increase in PSA) without evidence of metastatic disease is not considered an indication for intervention. Patients with symptomatic local progression are treated first with alpha blockers or mechanical intervention (e.g., transurethral resection of the prostate (TURP), transurethral incision of the prostate, stent placement). Patients with symptomatic regional progression undergo mechanical intervention, radiotherapy, or hormonal therapy, as indicated. Hormonal therapy is considered first-line therapy for patients with disease progression requiring nonmechanical therapy. Patients with disease that continues to progress or fails to respond to hormonal therapy undergo radiotherapy or chemotherapy. Patients with symptomatic local disease progression (defined as recurrent and persistent gross hematuria or bladder outlet obstruction) despite TURP, stents, and alpha blockers may undergo prostatectomy.
Quality of life is assessed at baseline and then every 6 months.
Patients are followed every 3 months for 1 year and then every 6 months for 15 years.Published Results
Wilt TJ, Brawer MK, Barry MJ, et al.: The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 30 (1): 81-7, 2009.[PUBMED Abstract]
Wilt TJ, Brawer MK: The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntingt) 11 (8): 1133-9; discussion 1139-40, 1143, 1997.[PUBMED Abstract]
Moon TD, Brawer MK, Wilt TJ: Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr (19): 69-71, 1995.[PUBMED Abstract]
Wilt TJ, Brawer MK: Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol 13 (2): 130-6, 1995.[PUBMED Abstract]
Wilt TJ, Brawer MK: The prostate cancer intervention versus observation trial (PIVOT): a randomized trial comparing radical prostectomy versus expectant management for the treatment of clinically localized prostate cancer. Cancer 75(7 Suppl): 1963-1968, 1995.
Wilt TJ, Brawer MK: The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 152 (5 Pt 2): 1910-4, 1994.[PUBMED Abstract]Related Publications
Screening for prostate cancer. American College of Physicians. Ann Intern Med 126 (6): 480-4, 1997.[PUBMED Abstract]
Trial Lead Organizations
Veterans Affairs Cooperative Studies Program Coordinating Center - Perry Point
|Timothy James Wilt, MD, MPH, Protocol chair|
Cancer and Leukemia Group B
|Timothy James Wilt, MD, MPH, Protocol chair|
Southwest Oncology Group
|Daniel Culkin, MD, FACS, Protocol chair (Contact information may not be current)|
Eastern Cooperative Oncology Group
|Timothy Moon, MD, FRCSC, MBChB, Protocol chair|
|Official Title||PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL (PIVOT): A RANDOMIZED TRIAL COMPARING RADICAL PROSTATECTOMY VERSUS PALLIATIVE EXPECTANT MANAGEMENT FOR THE TREATMENT OF CLINICALLY LOCALIZED PROSTATE CANCER|
|Registered in ClinicalTrials.gov||NCT00002606|
|Date Submitted to PDQ||1994-12-01|
|Information Last Verified||2003-04-18|
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.